News
Eli Lilly reports next week with Wall Street watching how its GLP-1 franchise holds up against intensifying competition — and how much AI investment is eating into margins. Shares closed Friday at $1,148.84, down 0.53%.
News
Eli Lilly’s Canadian unit scored a key win for its eczema drug Ebglyss, securing a positive reimbursement recommendation from the national drug agency and a letter of intent with the pan-Canadian alliance. The stock still closed down 2.33% on Wednesday.
News
The FDA selected seven drugmakers for its PreCheck pilot program, designed to speed regulatory reviews of new U.S. manufacturing facilities and bring pharmaceutical production back onshore.